Mylan Laboratories Limited Lenalidomide Export Data — India (DGFT 2022–2026)

Name: Mylan Laboratories Limited Lenalidomide Export Records India — #11 Exporter, 20 Shipments, $133.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Lenalidomide

India Pharmaceutical Trade Intelligence

$883.1M237 Suppliers122 CountriesHS 30049049

ExportsIndia → UNITED STATES96.7%India → JAPAN0.6%

ImportsUNITED STATES → India$1.6M SWITZERLAND → India$1.3M

#1 Supplier: SUN PHARMACEUTICAL #1 Buyer: SUN PHARMACEUTICAL

Mylan Laboratories Limited — Lenalidomide Exporter #11 | $133.2K Trade Value | TransData Nexus | TransData Nexus

Mylan Laboratories Limited — Lenalidomide Exporter Profile

Indian Pharmaceutical Exporter · #11 for Lenalidomide · $133.2K export value · DGFT Verified

Mylan Laboratories Limited is the #11 Indian exporter of Lenalidomide with $133.2K in export value and 20 verified shipments. Mylan Laboratories Limited holds a 0.1% market share in Lenalidomide exports across 6 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.

Mylan Laboratories Limited — Lenalidomide Export Profile: Buyers & Destinations

Mylan Laboratories Limited Lenalidomide export treemap — buyers and destination countries | TransData Nexus

Where Does Mylan Laboratories Limited Export Lenalidomide?

Country	Value	Shipments	Share
FRANCE	$65.3K	3	49.0%
NETHERLANDS	$31.6K	10	23.7%
UNITED STATES	$25.4K	4	19.1%
GERMANY	$5.7K	1	4.2%
AUSTRALIA

Who Are the Top Buyers of Lenalidomide from Mylan Laboratories Limited?

Buyer	Country	Value	Orders
XXLANXXRELXXD LXXITEXX NEXXNHAXXCOUXX MXXAHIXX RO	FRANCE	$107.8K	15
MYLAN PHARMACEUTICALS INC 3711 COLLINS FERRY ROAD	UNITED STATES	$25.4K	4
MYLAN HUNGARY KFT	HUNGARY	$1	1

Mylan Laboratories Limited supplies Lenalidomide to 3 buyers globally. The largest buyer is XXLANXXRELXXD LXXITEXX NEXXNHAXXCOUXX MXXAHIXX RO (FRANCE), followed by MYLAN PHARMACEUTICALS INC 3711 COLLINS FERRY ROAD (UNITED STATES) and MYLAN HUNGARY KFT (HUNGARY). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Lenalidomide Formulations Does Mylan Laboratories Limited Export?

Product Description / Formulation	Value	Shipments
LENALIDOMIDE CAP 20MG 21BL FR MY	$30.7K	1
LENALIDOMIDE CAP 25MG 21BL FR MY	$19.8K	1
LENALIDOMIDE CAP 15MG 21BL FR MY	$14.8K	1
LENALIDOMIDE CAP 25MG 100BT US MY	$10.4K	1
LENALIDOMIDE CAP 20MG 100BT US	$8.6K	1
LENALIDOMIDE CAP 15MG 21BL IE/IT MY	$7.6K	1
LENALIDOMIDE CAP 15MG 21BL DE MY	$5.7K	1
LENALIDOMIDE CAP 15MG 21BL	$5.6K	1
LENALIDOMIDE CAP 25MG 21BL ES/PT MY	$5.2K	1
LENALIDOMIDE CAP 15MG 21BL AU VIA	$5.2K	1

Mylan Laboratories Limited exports 20 distinct Lenalidomide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LENALIDOMIDE CAP 20MG 21BL FR MY with 1 shipments worth $30.7K.

How Does Mylan Laboratories Limited Compare to Nearest Lenalidomide Exporters?

Exporters ranked immediately above and below #11 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
9	SP ACCURE LABS PRIVATE LIMITED	$149.5K	7	2	$21.4K
10	RMPL PHARMA LLP	$145.7K	82	10	$1.8K
11	MYLAN LABORATORIES LIMITED ★	$133.2K	20	6	$6.7K
12	BETA DRUGS LIMITED	$110.3K	66	10	$1.7K
13	CAPLIN POINT LABORATORIES LIMITED	$107.3K	4	1	$26.8K

Mylan Laboratories Limited ranks #11 among 237 Indian Lenalidomide exporters. Average shipment value of $6.7K compared to the market average of $128.1K. The closest competitors by value are SP ACCURE LABS PRIVATE LIMITED and RMPL PHARMA LLP.

Which Indian Ports Ship Lenalidomide Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	740	27.2%
SAHAR AIR	688	25.3%
DELHI AIR CARGO ACC (INDEL4)	187	6.9%
Bombay Air	180	6.6%
DELHI AIR	140	5.1%
Bombay Air Cargo	88	3.2%
HYDERABAD ACC (INHYD4)	78	2.9%
HYDERABAD AIR	68	2.5%

Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Lenalidomide Exports

Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.

In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.

Mylan Laboratories Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.

The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Lenalidomide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 20 individual customs records matching Mylan Laboratories Limited exporting Lenalidomide, covering 20 formulations to 6 countries via 3 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 122+ countries, 557+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Lenalidomide

Lenalidomide

Mylan Laboratories Limited — Lenalidomide Exporter Profile

Mylan Laboratories Limited — Lenalidomide Export Profile: Buyers & Destinations

Where Does Mylan Laboratories Limited Export Lenalidomide?

Who Are the Top Buyers of Lenalidomide from Mylan Laboratories Limited?

What Is India's Total Lenalidomide Export Value and How Much Does Mylan Laboratories Limited Contribute?

What Is the Average Shipment Value for Mylan Laboratories Limited's Lenalidomide Exports?

How Does Mylan Laboratories Limited Compare to Other Indian Lenalidomide Exporters?

What Lenalidomide Formulations Does Mylan Laboratories Limited Export?

Regulatory Requirements: Exporting Lenalidomide to Key Markets

United States — FDA

How Does Mylan Laboratories Limited Compare to Nearest Lenalidomide Exporters?

Which Indian Ports Ship Lenalidomide Exports?

Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Lenalidomide Exports

Mylan Laboratories Limited — Regulatory Compliance & Quality Standards

About Mylan Laboratories Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Lenalidomide Export Data from Mylan Laboratories Limited

Lenalidomide Stats

Company Overview

Top Products by Mylan Laboratories Limited

Related Analysis

Need Detailed Export Data?

Data Source